{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-093353","form_type":"8-K","ticker":"ALMS","cik":"0001847367","company_name":"ALUMIS INC.","filed_at":"2026-08-10T20:06:06+00:00","discovered_at":"2026-08-10T20:07:01.470364+00:00","generated_at":"2026-08-10T20:07:13.994869+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Envudeucitinib achieves 54% PASI 100 at 48 weeks; NDA on track for 4Q 2026","bullets":["54% of patients achieved PASI 100 (complete skin clearance) at 48 weeks; 75% achieved PASI 90.","Integrated analysis (890 pts) showed 66% PASI 90 and 47% PASI 100 at 48 weeks.","1,509 patients rolled into ONWARD3 from ONWARD1/2 (>85% rollover); safety consistent, no new signals.","NDA submission to FDA planned for 4Q 2026; LUMUS Phase 2b SLE topline expected 3Q 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-093353","json":"https://secwatch.observer/filing/0001104659-26-093353.json","markdown":"https://secwatch.observer/filing/0001104659-26-093353.md","text":"https://secwatch.observer/filing/0001104659-26-093353.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/0001104659-26-093353-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T20:07:13.994869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}